 | • レポートコード：MRC2-11QY03930 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は腎芽腫治療のグローバル市場について調査・分析したレポートです。種類別（ダクチノマイシン、ドキソルビシン、ビンクリスチン、シクロホスファミド、エトポシド、イリノテカン）市場規模、用途別（病院、がんセンター、外科センター、外来外科センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別腎芽腫治療の競争状況、市場シェア ・世界の腎芽腫治療市場：種類別市場規模 2015年-2020年（ダクチノマイシン、ドキソルビシン、ビンクリスチン、シクロホスファミド、エトポシド、イリノテカン） ・世界の腎芽腫治療市場：種類別市場規模予測 2021年-2026年（ダクチノマイシン、ドキソルビシン、ビンクリスチン、シクロホスファミド、エトポシド、イリノテカン） ・世界の腎芽腫治療市場：用途別市場規模 2015年-2020年（病院、がんセンター、外科センター、外来外科センター） ・世界の腎芽腫治療市場：用途別市場規模予測 2021年-2026年（病院、がんセンター、外科センター、外来外科センター） ・北米の腎芽腫治療市場分析：米国、カナダ ・ヨーロッパの腎芽腫治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの腎芽腫治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の腎芽腫治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの腎芽腫治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bayer HealthCare、Roche、Pfizer、Sanofi Pasteur、Merck、MediLexicon、Bristol-Myers Squibb Company、Apotex ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Nephroblastoma is a cancer of the kidneys that typically occurs in children, rarely in adults. Approximately 500 cases are diagnosed in the U.S. annually. The majority (75%) occurs in otherwise normal children; a minority (25%) is associated with other developmental abnormalities. It is highly responsive to treatment, with about 90% of patients surviving at least five years.
The overall 5-year survival is estimated to be approximately 90%, but for individuals the prognosis is highly dependent on individual staging and treatment. Early removal tends to promote positive outcomes.
Market Analysis and Insights: Global Nephroblastoma Treatment Market
The global Nephroblastoma Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Nephroblastoma Treatment Scope and Market Size
Nephroblastoma Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Nephroblastoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Bayer HealthCare
Roche
Pfizer
Sanofi Pasteur
Merck
MediLexicon
Bristol-Myers Squibb Company
Apotex
Market segment by Type, the product can be split into
Dactinomycin
Doxorubicin
Vincristine
Cyclophosphamide
Etoposide
Irinotecan
Market segment by Application, split into
Hospitals
Cancer Centers
Surgical Centers
Ambulatory Surgical Center
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Nephroblastoma Treatment Revenue
1.4 Market by Type
1.4.1 Global Nephroblastoma Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Dactinomycin
1.4.3 Doxorubicin
1.4.4 Vincristine
1.4.5 Cyclophosphamide
1.4.6 Etoposide
1.4.7 Irinotecan
1.5 Market by Application
1.5.1 Global Nephroblastoma Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Centers
1.5.4 Surgical Centers
1.5.5 Ambulatory Surgical Center
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Nephroblastoma Treatment Market Perspective (2015-2026)
2.2 Global Nephroblastoma Treatment Growth Trends by Regions
2.2.1 Nephroblastoma Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Nephroblastoma Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Nephroblastoma Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Nephroblastoma Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Nephroblastoma Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Nephroblastoma Treatment Players by Market Size
3.1.1 Global Top Nephroblastoma Treatment Players by Revenue (2015-2020)
3.1.2 Global Nephroblastoma Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Nephroblastoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Nephroblastoma Treatment Market Concentration Ratio
3.2.1 Global Nephroblastoma Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Nephroblastoma Treatment Revenue in 2019
3.3 Nephroblastoma Treatment Key Players Head office and Area Served
3.4 Key Players Nephroblastoma Treatment Product Solution and Service
3.5 Date of Enter into Nephroblastoma Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Nephroblastoma Treatment Historic Market Size by Type (2015-2020)
4.2 Global Nephroblastoma Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Nephroblastoma Treatment Market Size by Application (2015-2020)
5.2 Global Nephroblastoma Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Nephroblastoma Treatment Market Size (2015-2020)
6.2 Nephroblastoma Treatment Key Players in North America (2019-2020)
6.3 North America Nephroblastoma Treatment Market Size by Type (2015-2020)
6.4 North America Nephroblastoma Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Nephroblastoma Treatment Market Size (2015-2020)
7.2 Nephroblastoma Treatment Key Players in Europe (2019-2020)
7.3 Europe Nephroblastoma Treatment Market Size by Type (2015-2020)
7.4 Europe Nephroblastoma Treatment Market Size by Application (2015-2020)
8 China
8.1 China Nephroblastoma Treatment Market Size (2015-2020)
8.2 Nephroblastoma Treatment Key Players in China (2019-2020)
8.3 China Nephroblastoma Treatment Market Size by Type (2015-2020)
8.4 China Nephroblastoma Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Nephroblastoma Treatment Market Size (2015-2020)
9.2 Nephroblastoma Treatment Key Players in Japan (2019-2020)
9.3 Japan Nephroblastoma Treatment Market Size by Type (2015-2020)
9.4 Japan Nephroblastoma Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Nephroblastoma Treatment Market Size (2015-2020)
10.2 Nephroblastoma Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Nephroblastoma Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Nephroblastoma Treatment Market Size by Application (2015-2020)
11 India
11.1 India Nephroblastoma Treatment Market Size (2015-2020)
11.2 Nephroblastoma Treatment Key Players in India (2019-2020)
11.3 India Nephroblastoma Treatment Market Size by Type (2015-2020)
11.4 India Nephroblastoma Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Nephroblastoma Treatment Market Size (2015-2020)
12.2 Nephroblastoma Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Nephroblastoma Treatment Market Size by Type (2015-2020)
12.4 Central & South America Nephroblastoma Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Bayer HealthCare
13.1.1 Bayer HealthCare Company Details
13.1.2 Bayer HealthCare Business Overview
13.1.3 Bayer HealthCare Nephroblastoma Treatment Introduction
13.1.4 Bayer HealthCare Revenue in Nephroblastoma Treatment Business (2015-2020))
13.1.5 Bayer HealthCare Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Nephroblastoma Treatment Introduction
13.2.4 Roche Revenue in Nephroblastoma Treatment Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Nephroblastoma Treatment Introduction
13.3.4 Pfizer Revenue in Nephroblastoma Treatment Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Sanofi Pasteur
13.4.1 Sanofi Pasteur Company Details
13.4.2 Sanofi Pasteur Business Overview
13.4.3 Sanofi Pasteur Nephroblastoma Treatment Introduction
13.4.4 Sanofi Pasteur Revenue in Nephroblastoma Treatment Business (2015-2020)
13.4.5 Sanofi Pasteur Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Nephroblastoma Treatment Introduction
13.5.4 Merck Revenue in Nephroblastoma Treatment Business (2015-2020)
13.5.5 Merck Recent Development
13.6 MediLexicon
13.6.1 MediLexicon Company Details
13.6.2 MediLexicon Business Overview
13.6.3 MediLexicon Nephroblastoma Treatment Introduction
13.6.4 MediLexicon Revenue in Nephroblastoma Treatment Business (2015-2020)
13.6.5 MediLexicon Recent Development
13.7 Bristol-Myers Squibb Company
13.7.1 Bristol-Myers Squibb Company Company Details
13.7.2 Bristol-Myers Squibb Company Business Overview
13.7.3 Bristol-Myers Squibb Company Nephroblastoma Treatment Introduction
13.7.4 Bristol-Myers Squibb Company Revenue in Nephroblastoma Treatment Business (2015-2020)
13.7.5 Bristol-Myers Squibb Company Recent Development
13.8 Apotex
13.8.1 Apotex Company Details
13.8.2 Apotex Business Overview
13.8.3 Apotex Nephroblastoma Treatment Introduction
13.8.4 Apotex Revenue in Nephroblastoma Treatment Business (2015-2020)
13.8.5 Apotex Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Nephroblastoma Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Nephroblastoma Treatment Revenue
Table 3. Ranking of Global Top Nephroblastoma Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Nephroblastoma Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Dactinomycin
Table 6. Key Players of Doxorubicin
Table 7. Key Players of Vincristine
Table 8. Key Players of Cyclophosphamide
Table 9. Key Players of Etoposide
Table 10. Key Players of Irinotecan
Table 11. Global Nephroblastoma Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Nephroblastoma Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Nephroblastoma Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Nephroblastoma Treatment Market Share by Regions (2015-2020)
Table 15. Global Nephroblastoma Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Nephroblastoma Treatment Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Nephroblastoma Treatment Market Growth Strategy
Table 21. Main Points Interviewed from Key Nephroblastoma Treatment Players
Table 22. Global Nephroblastoma Treatment Revenue by Players (2015-2020) (Million US$)
Table 23. Global Nephroblastoma Treatment Market Share by Players (2015-2020)
Table 24. Global Top Nephroblastoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nephroblastoma Treatment as of 2019)
Table 25. Global Nephroblastoma Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Nephroblastoma Treatment Product Solution and Service
Table 28. Date of Enter into Nephroblastoma Treatment Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Nephroblastoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 31. Global Nephroblastoma Treatment Market Size Share by Type (2015-2020)
Table 32. Global Nephroblastoma Treatment Revenue Market Share by Type (2021-2026)
Table 33. Global Nephroblastoma Treatment Market Size Share by Application (2015-2020)
Table 34. Global Nephroblastoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 35. Global Nephroblastoma Treatment Market Size Share by Application (2021-2026)
Table 36. North America Key Players Nephroblastoma Treatment Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Nephroblastoma Treatment Market Share (2019-2020)
Table 38. North America Nephroblastoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 39. North America Nephroblastoma Treatment Market Share by Type (2015-2020)
Table 40. North America Nephroblastoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 41. North America Nephroblastoma Treatment Market Share by Application (2015-2020)
Table 42. Europe Key Players Nephroblastoma Treatment Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Nephroblastoma Treatment Market Share (2019-2020)
Table 44. Europe Nephroblastoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Nephroblastoma Treatment Market Share by Type (2015-2020)
Table 46. Europe Nephroblastoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Nephroblastoma Treatment Market Share by Application (2015-2020)
Table 48. China Key Players Nephroblastoma Treatment Revenue (2019-2020) (Million US$)
Table 49. China Key Players Nephroblastoma Treatment Market Share (2019-2020)
Table 50. China Nephroblastoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 51. China Nephroblastoma Treatment Market Share by Type (2015-2020)
Table 52. China Nephroblastoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 53. China Nephroblastoma Treatment Market Share by Application (2015-2020)
Table 54. Japan Key Players Nephroblastoma Treatment Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Nephroblastoma Treatment Market Share (2019-2020)
Table 56. Japan Nephroblastoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Nephroblastoma Treatment Market Share by Type (2015-2020)
Table 58. Japan Nephroblastoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Nephroblastoma Treatment Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Nephroblastoma Treatment Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Nephroblastoma Treatment Market Share (2019-2020)
Table 62. Southeast Asia Nephroblastoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Nephroblastoma Treatment Market Share by Type (2015-2020)
Table 64. Southeast Asia Nephroblastoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Nephroblastoma Treatment Market Share by Application (2015-2020)
Table 66. India Key Players Nephroblastoma Treatment Revenue (2019-2020) (Million US$)
Table 67. India Key Players Nephroblastoma Treatment Market Share (2019-2020)
Table 68. India Nephroblastoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 69. India Nephroblastoma Treatment Market Share by Type (2015-2020)
Table 70. India Nephroblastoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 71. India Nephroblastoma Treatment Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Nephroblastoma Treatment Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Nephroblastoma Treatment Market Share (2019-2020)
Table 74. Central & South America Nephroblastoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Nephroblastoma Treatment Market Share by Type (2015-2020)
Table 76. Central & South America Nephroblastoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Nephroblastoma Treatment Market Share by Application (2015-2020)
Table 78. Bayer HealthCare Company Details
Table 79. Bayer HealthCare Business Overview
Table 80. Bayer HealthCare Product
Table 81. Bayer HealthCare Revenue in Nephroblastoma Treatment Business (2015-2020) (Million US$)
Table 82. Bayer HealthCare Recent Development
Table 83. Roche Company Details
Table 84. Roche Business Overview
Table 85. Roche Product
Table 86. Roche Revenue in Nephroblastoma Treatment Business (2015-2020) (Million US$)
Table 87. Roche Recent Development
Table 88. Pfizer Company Details
Table 89. Pfizer Business Overview
Table 90. Pfizer Product
Table 91. Pfizer Revenue in Nephroblastoma Treatment Business (2015-2020) (Million US$)
Table 92. Pfizer Recent Development
Table 93. Sanofi Pasteur Company Details
Table 94. Sanofi Pasteur Business Overview
Table 95. Sanofi Pasteur Product
Table 96. Sanofi Pasteur Revenue in Nephroblastoma Treatment Business (2015-2020) (Million US$)
Table 97. Sanofi Pasteur Recent Development
Table 98. Merck Company Details
Table 99. Merck Business Overview
Table 100. Merck Product
Table 101. Merck Revenue in Nephroblastoma Treatment Business (2015-2020) (Million US$)
Table 102. Merck Recent Development
Table 103. MediLexicon Company Details
Table 104. MediLexicon Business Overview
Table 105. MediLexicon Product
Table 106. MediLexicon Revenue in Nephroblastoma Treatment Business (2015-2020) (Million US$)
Table 107. MediLexicon Recent Development
Table 108. Bristol-Myers Squibb Company Company Details
Table 109. Bristol-Myers Squibb Company Business Overview
Table 110. Bristol-Myers Squibb Company Product
Table 111. Bristol-Myers Squibb Company Revenue in Nephroblastoma Treatment Business (2015-2020) (Million US$)
Table 112. Bristol-Myers Squibb Company Recent Development
Table 113. Apotex Business Overview
Table 114. Apotex Product
Table 115. Apotex Company Details
Table 116. Apotex Revenue in Nephroblastoma Treatment Business (2015-2020) (Million US$)
Table 117. Apotex Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nephroblastoma Treatment Market Share by Type: 2020 VS 2026
Figure 2. Dactinomycin Features
Figure 3. Doxorubicin Features
Figure 4. Vincristine Features
Figure 5. Cyclophosphamide Features
Figure 6. Etoposide Features
Figure 7. Irinotecan Features
Figure 8. Global Nephroblastoma Treatment Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Cancer Centers Case Studies
Figure 11. Surgical Centers Case Studies
Figure 12. Ambulatory Surgical Center Case Studies
Figure 13. Nephroblastoma Treatment Report Years Considered
Figure 14. Global Nephroblastoma Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Nephroblastoma Treatment Market Share by Regions: 2020 VS 2026
Figure 16. Global Nephroblastoma Treatment Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Nephroblastoma Treatment Market Share by Players in 2019
Figure 19. Global Top Nephroblastoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nephroblastoma Treatment as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Nephroblastoma Treatment Revenue in 2019
Figure 21. North America Nephroblastoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Nephroblastoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Nephroblastoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Nephroblastoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Nephroblastoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Nephroblastoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Nephroblastoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed
非血液がん治療の世界市場（～2026年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…- 甲状腺がん治療の世界市場（～2026年） Market Analysis and Insights: Global Thyroid Cancer Treatment Market The global Thyroid Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Thyroid Cancer Treatment Scope and Market Size Thyroid Cancer Tre…
- 下咽頭がん治療の世界市場（～2026年） Market Analysis and Insights: Global Hypopharyngeal Cancer Treatment Market The global Hypopharyngeal Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Hypopharyngeal Cancer Treatment Scope and Market Si…
- 非黒色腫皮膚がん治療の世界市場（～2026年） Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts. Radiation therapy has a market share approaching 88% in the non-melanoma skin cancer treatment market in 2017 itself and is unlike…
- 転移性がん治療の世界市場（～2026年） Metastatic breast cancer is an advanced stage of breast cancer. It involves cases in which breast cancer has spread to the other parts of the body. Some of the most common organs which are affected by metastatic breast cancer are brain, liver, bones and lungs. It is also known as stage IV breast can…